Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lomustine + etoposide + methotrexate
- Development stage
- Unknown
- Lead developer
- NextSource Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination chemotherapy regimen consisting of lomustine (CCNU), etoposide, and methotrexate. This regimen has been studied primarily for the treatment of small cell lung cancer (SCCL). Clinical trials have investigated different administration schedules to determine optimal efficacy, with some evidence suggesting that the timing of etoposide administration may impact treatment outcomes.
- Other names
- CCNU + etoposide + methotrexate
02
Targets
DHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on lomustine + etoposide + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lomustine + etoposide + methotrexate.